The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
High-frequency off-target mutagenesis induced by CRISPR-Cas nucleases in human cells
Open accessAbstract
Clustered, regularly interspaced, short palindromic repeat (CRISPR) RNA-guided nucleases (RGNs) have rapidly emerged as a facile and efficient platform for genome editing. Here, we use a human cell-based reporter assay to characterize off-target cleavage of CRISPR-associated (Cas)9-based RGNs. We find that single and double mismatches are tolerated to varying degrees depending on their position along the guide RNA (gRNA)-DNA interface. We also readily detected off-target alterations induced by four out of six RGNs targeted to endogenous loci in human cells by examination of partially mismatched sites. The off-target sites we identified harbored up to five mismatches and many were mutagenized with frequencies comparable to (or higher than) those observed at the intended on-target site. Our work demonstrates that RGNs can be highly active even with imperfectly matched RNA-DNA interfaces in human cells, a finding that might confound their use in research and therapeutic applications.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Moreover, in-depth studies on the outcomes of Cas9-induced double-strand break (DSB) repair have shown significant off-target effects, which resulted in substitution, insertion, deletion, and DNA translocation.”
From Machine learning-based prediction models to guide the selection of Cas9 variants for efficient gene editing (2024) · cites this paper as [13]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Defective off-target binding and cleaving can result in collateral mutagenesis induced by the error-prone repair of DSB by NHEJ [106,107].”
From CRISPR-Cas: Converting A Bacterial Defence Mechanism into A State-of-the-Art Genetic Manipulation Tool (2019) · cites this paper as [107]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“For example, a study demonstrated that manipulating Cas9's biophysical attributes, such as minimizing nonspecific RNA-DNA interactions, significantly reduces off-target mutations while maintaining high on-target efficiency.”
From Hybrid Neural Networks for Off-Target Prediction in Gene Editing: Integrating Sequence and Biophysical Features (2025) · cites this paper as [5]
Experimental — accuracy not yet measuredIn the citing paper
“A study reported highfrequency off-target mutagenesis in transduced human cell lines after SpCas9 delivery [108].”
From Immune responses to gene editing by viral and non-viral delivery vectors used in retinal gene therapy (2022) · cites this paper as [108]
In the citing paper
“Using a VEGFA sgRNA with well-characterized off-target sites24, we observed that transient Cas9 expression by mRNA delivery can substantially reduce off-target genome editing in cells (Fig. 1f–h).”
From Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo (2016) · cites this paper as [24]
In the citing paper
“as mentioned in several recent publications, Cas9 tolerates mismatches between the guide RNA and target DNA in a sequence-dependent manner and potentially tolerates up to five target mismatches in human cells [12], [24], [25], [26], [27], thereby promoting undesired off-target mutations.”
From High-efficiency targeted editing of large viral genomes by RNA-guided nucleases (2014) · cites this paper as [24]
In the citing paper
“non-specific cleavage may occur in the cellular genome [12], [24], [25], [26], [27].”
From High-efficiency targeted editing of large viral genomes by RNA-guided nucleases (2014) · cites this paper as [24]
In the citing paper
“Because the sequence specificity of Streptococcus pyogenes Cas9 tolerates 4 mismatches between the gRNA and complementary sequence”
From High-efficiency targeted editing of large viral genomes by RNA-guided nucleases (2014) · cites this paper as [24]
In the citing paper
“Collectively, these studies indicate that although each base within the 20 nt guide sequence contributes to overall specificity”
From Newer Gene Editing Technologies toward HIV Gene Therapy (2013) · cites this paper as [90]
In the citing paper
“However, it has been recently shown that CRISPR/Cas9 system can be highly active even when mismatches occur between gRNA and their DNA targets”
From Newer Gene Editing Technologies toward HIV Gene Therapy (2013) · cites this paper as [90]
In the citing paper
“multiple mismatches between the guide RNA and its complementary target DNA sequence can be tolerated depending on the quantity, position, and base identity of mismatches [87,90,91,93], all of which contribute to potential off-target activity.”
From Newer Gene Editing Technologies toward HIV Gene Therapy (2013) · cites this paper as [90]
In the citing paper
“and off-target mutations occur at endogenous loci in human cells with high frequency [90,91,92].”
From Newer Gene Editing Technologies toward HIV Gene Therapy (2013) · cites this paper as [90]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity
Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J. A., & Charpentier, E. (2012) · Science · doi:10.1126/science.1225829 · Cited by 17,116
Multiplex Genome Engineering Using CRISPR/Cas Systems
Cong, L., Ran, F. A., Cox, D., Lin, S., Barretto, R., Habib, N., Hsu, P. D., Wu, X., Jiang, W., Marraffini, L. A., et al. (2013) · Science · doi:10.1126/science.1231143 · Cited by 15,339
RNA-Guided Human Genome Engineering via Cas9
Mali, P., Yang, L., Esvelt, K. M., Aach, J., Guell, M., DiCarlo, J. E., Norville, J. E., & Church, G. M. (2013) · Science · doi:10.1126/science.1232033 · Cited by 9,210
Wang, H., Yang, H., Shivalila, C. S., Dawlaty, M. M., Cheng, A. W., Zhang, F., & Jaenisch, R. (2013) · Cell · doi:10.1016/j.cell.2013.04.025 · Cited by 3,495
Efficient genome editing in zebrafish using a CRISPR-Cas system
Hwang, W. Y., Fu, Y., Reyon, D., Maeder, M. L., Tsai, S. Q., Sander, J. D., Peterson, R. T., Yeh, J.-R. J., & Joung, J. K. (2013) · Nature Biotechnology · doi:10.1038/nbt.2501 · Cited by 2,937
CRISPR/Cas, the Immune System of Bacteria and Archaea
Horvath, P., & Barrangou, R. (2010) · Science · doi:10.1126/science.1179555 · Cited by 2,471
RNA-guided editing of bacterial genomes using CRISPR-Cas systems
Jiang, W., Bikard, D., Cox, D., Zhang, F., & Marraffini, L. A. (2013) · Nature Biotechnology · doi:10.1038/nbt.2508 · Cited by 2,429
RNA-programmed genome editing in human cells
Jinek, M., East, A., Cheng, A., Lin, S., Ma, E., & Doudna, J. (2013) · eLife · doi:10.7554/elife.00471 · Cited by 2,098
Targeted genome engineering in human cells with the Cas9 RNA-guided endonuclease
Cho, S. W., Kim, S., Kim, J. M., & Kim, J.-S. (2013) · Nature Biotechnology · doi:10.1038/nbt.2507 · Cited by 1,863
RNA-guided genetic silencing systems in bacteria and archaea
Wiedenheft, B., Sternberg, S. H., & Doudna, J. A. (2012) · Nature · doi:10.1038/nature10886 · Cited by 1,851
Flagged first, then by citations
Cited by
Sorted by citations
Items 401–500 of 1,023
Mouse Genome Editing Using the CRISPR/Cas System
Harms, D. W., Quadros, R. M., Seruggia, D., Ohtsuka, M., Takahashi, G., Montoliu, L., & Gurumurthy, C. B. (2014) · Current Protocols in Human Genetics · doi:10.1002/0471142905.hg1507s83 · Cited by 153
Quantifying on- and off-target genome editing
Hendel, A., Fine, E. J., Bao, G., & Porteus, M. H. (2015) · Trends in biotechnology · doi:10.1016/j.tibtech.2014.12.001 · Cited by 151
Genome-editing technologies and their potential application in horticultural crop breeding
Xiong, J., Ding, J., & Li, Y. (2015) · Horticulture Research · doi:10.1038/hortres.2015.19 · Cited by 152
CRISPR-Cas9 off-targeting assessment with nucleic acid duplex energy parameters
Alkan, F., Wenzel, A., Anthon, C., Havgaard, J. H., & Gorodkin, J. (2018) · Genome biology · doi:10.1186/s13059-018-1534-x · Cited by 174
Chang, J., Kim, Y., & Kwon, H. J. (2016) · Natural Product Reports · doi:10.1039/c5np00107b · Cited by 151
Spatial control of in vivo CRISPR–Cas9 genome editing via nanomagnets
Zhu, H., Zhang, L., Tong, S., Lee, C. M., Deshmukh, H., & Bao, G. (2018) · Nature Biomedical Engineering · doi:10.1038/s41551-018-0318-7 · Cited by 151
Modrzejewski, D., Hartung, F., Lehnert, H., Sprink, T., Kohl, C., Keilwagen, J., & Wilhelm, R. (2020) · Frontiers in Plant Science · doi:10.3389/fpls.2020.574959 · Cited by 151
Genome engineering via TALENs and CRISPR/Cas9 systems: challenges and perspectives
Mahfouz, M. M., Piatek, A., & Stewart, C. N. (2014) · Plant Biotechnology Journal · doi:10.1111/pbi.12256 · Cited by 154
Heptad-Specific Phosphorylation of RNA Polymerase II CTD
Schüller, R., Forné, I., Straub, T., Schreieck, A., Texier, Y., Shah, N., Decker, T.-M., Cramer, P., Imhof, A., & Eick, D. (2016) · Molecular Cell · doi:10.1016/j.molcel.2015.12.003 · Cited by 150
Ortinski, P. I., O’Donovan, B., Dong, X., & Kantor, B. (2017) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2017.04.002 · Cited by 146
Genome-wide profiling of adenine base editor specificity by EndoV-seq
Liang, P., Xie, X., Zhi, S., Sun, H., Zhang, X., Chen, Y., Chen, Y., Xiong, Y., Ma, W., Liu, D., et al. (2019) · Nature Communications · doi:10.1038/s41467-018-07988-z · Cited by 148
Efficient Editing of Malaria Parasite Genome Using the CRISPR/Cas9 System
Zhang, C., Xiao, B., Jiang, Y., Zhao, Y., Li, Z., Gao, H., Ling, Y., Wei, J., Li, S., Lu, M., et al. (2014) · mBio · doi:10.1128/mbio.01414-14 · Cited by 149
Tóth, E., Varga, É., Kulcsár, P. I., Kocsis-Jutka, V., Krausz, S. L., Nyeste, A., Welker, Z., Huszár, K., Ligeti, Z., Tálas, A., et al. (2020) · Nucleic Acids Research · doi:10.1093/nar/gkaa110 · Cited by 147
TALENs—an indispensable tool in the era of CRISPR: a mini review
Bhardwaj, A., & Nain, V. (2021) · Journal of Genetic Engineering and Biotechnology · doi:10.1186/s43141-021-00225-z · Cited by 162
High-efficiency targeted editing of large viral genomes by RNA-guided nucleases
Bi, Y., Sun, L., Gao, D., Ding, C., Li, Z., Li, Y., Cun, W., & Li, Q. (2014) · PLoS Pathogens · doi:10.1371/journal.ppat.1004090 · Cited by 148
Berdien, B., Mock, U., Atanackovic, D., & Fehse, B. (2014) · Gene Therapy · doi:10.1038/gt.2014.26 · Cited by 149
Park, S. H., Lee, C. M., Dever, D. P., Davis, T., Camarena, J., Srifa, W., Zhang, Y., Paikari, A., Chang, A. K., Porteus, M. H., et al. (2019) · Nucleic Acids Research · doi:10.1093/nar/gkz475 · Cited by 152
Merkle, F. T., Neuhausser, W. M., Santos, D., Valen, E., Gagnon, J. A., Maas, K., Sandoe, J., Schier, A. F., & Eggan, K. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.04.007 · Cited by 152
CRISPR technologies for bacterial systems: Current achievements and future directions
Choi, K. R., & Lee, S. Y. (2016) · Biotechnology Advances · doi:10.1016/j.biotechadv.2016.08.002 · Cited by 151
Jacobi, A. M., Rettig, G. R., Turk, R., Collingwood, M. A., Zeiner, S. A., Quadros, R. M., Harms, D. W., Bonthuis, P. J., Gregg, C. J., Ohtsuka, M., et al. (2017) · Methods · doi:10.1016/j.ymeth.2017.03.021 · Cited by 142
Li, P., Estrada, J., Burlak, C., Montgomery, J. B., Butler, J. R., Miyashiro, R., Wang, Z., Paris, L. L., Blankenship, R. L., Downey, S. M., et al. (2014) · Xenotransplantation · doi:10.1111/xen.12131 · Cited by 146
A Pan-ALDH1A Inhibitor Induces Necroptosis in Ovarian Cancer Stem-like Cells
Chefetz, I., Grimley, E. C., Yang, K. Y., Hong, L., Vinogradova, E. V., Suciu, R. M., Kovalenko, I., Karnak, D. M., Morgan, C. A., Chtcherbinine, M., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.02.032 · Cited by 152
Deciphering Off-Target Effects in CRISPR-Cas9 through Accelerated Molecular Dynamics
Ricci, C. G., Chen, J. S., Miao, Y., Jínek, M., Doudna, J. A., McCammon, J. A., & Palermo, G. (2019) · ACS Central Science · doi:10.1021/acscentsci.9b00020 · Cited by 153
Efficient Generation of Myostatin Gene Mutated Rabbit by CRISPR/Cas9
Lv, Q., Yuan, L., Deng, J., Chen, M., Wang, Y., Zeng, J., Li, Z., & Lai, L. (2016) · Scientific Reports · doi:10.1038/srep25029 · Cited by 146
Functional CRISPR screening identifies the ufmylation pathway as a regulator of SQSTM1/p62
DeJesus, R., Moretti, F., McAllister, G., Wang, Z., Bergman, P., Liu, S., Frias, E., Alford, J., Reece-Hoyes, J. S., Lindeman, A., et al. (2016) · eLife · doi:10.7554/elife.17290 · Cited by 140
Kim, H. K., Lee, S., Kim, Y., Park, J., Min, S., Choi, J. W., Huang, T. P., Yoon, S., Liu, D. R., & Kim, H. H. (2020) · Nature Biomedical Engineering · doi:10.1038/s41551-019-0505-1 · Cited by 145
Delivery of CRISPR/Cas9 for therapeutic genome editing
Xu, X., Wan, T., Xin, H., Li, D., Pan, H., Wu, J., & Ping, Y. (2019) · The Journal of Gene Medicine · doi:10.1002/jgm.3107 · Cited by 134
Wyvekens, N., Topkar, V. V., Khayter, C., Joung, J. K., & Tsai, S. Q. (2015) · Human Gene Therapy · doi:10.1089/hum.2015.084 · Cited by 147
Self-citationBersell, K. R., Choudhury, S., Mollova, M., Polizzotti, B. D., Ganapathy, B., Walsh, S., Wadugu, B. A., Arab, S., & Kühn, B. (2013) · Disease Models & Mechanisms · doi:10.1242/dmm.010447 · Cited by 143
Ohmori, T., Nagao, Y., Mizukami, H., Sakata, A., Muramatsu, S., Ozawa, K., Tominaga, S., Hanazono, Y., Nishimura, S., Nureki, O., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-04625-5 · Cited by 144
Genome-wide identification of CRISPR/Cas9 off-targets in human genome
Duan, J., Lu, G., Xie, Z., Lou, M., Luo, J., Guo, L., & Zhang, Y. (2014) · Cell Research · doi:10.1038/cr.2014.87 · Cited by 137
Functional characterization of SlitPBP3 in Spodoptera litura by CRISPR/Cas9 mediated genome editing
Zhu, G., Xu, J. Q., Cui, Z., Dong, X., Ye, Z., Niu, D.-J., Huang, Y., & Dong, S. (2016) · Insect Biochemistry and Molecular Biology · doi:10.1016/j.ibmb.2016.05.006 · Cited by 142
Maggio, I., Holkers, M., Liu, J., Janssen, J. M., Chen, X., & Gonçalves, M. A. F. V. (2014) · Scientific Reports · doi:10.1038/srep05105 · Cited by 139
Mianné, J., Chessum, L., Kumar, S., Aguilar, C., Codner, G. F., Hutchison, M., Parker, A. J., Mallon, A., Wells, S. E., Simon, M. M., et al. (2016) · Genome Medicine · doi:10.1186/s13073-016-0273-4 · Cited by 138
Li, J., Zhang, B., Ren, Y., Gu, S., Xiang, Y., Huang, C., & Du, J. (2015) · Cell Research · doi:10.1038/cr.2015.43 · Cited by 140
High‐efficiency genome editing using a dmc1 promoter‐controlled CRISPR /Cas9 system in maize
Feng, C., Su, H., Bai, H., Wang, R., Liu, Y., Guo, X., Liu, C., Zhang, J., Yuan, J., Birchler, J. A., et al. (2018) · Plant Biotechnology Journal · doi:10.1111/pbi.12920 · Cited by 136
Adenoviral vector DNA for accurate genome editing with engineered nucleases
Holkers, M., Maggio, I., Henriques, S. F. D., Janssen, J. M., Cathomen, T., & Gonçalves, M. A. F. V. (2014) · Nature Methods · doi:10.1038/nmeth.3075 · Cited by 138
Evaluating CRISPR-based prime editing for cancer modeling and CFTR repair in organoids
Geurts, M. H., de Poel, E., Pleguezuelos-Manzano, C., Oka, R., Carrillo, L., Andersson-Rolf, A., Boretto, M., Brunsveld, J. E., van Boxtel, R., Beekman, J. M., et al. (2021) · Life Science Alliance · doi:10.26508/lsa.202000940 · Cited by 151
Neggers, J. E., Vercruysse, T., Jacquemyn, M., Vanstreels, E., Baloglu, E., Shacham, S., Crochiere, M. L., Landesman, Y., & Daelemans, D. (2015) · Chemistry & Biology · doi:10.1016/j.chembiol.2014.11.015 · Cited by 139
Nielsen, A. A. K., Segall-Shapiro, T. H., & Voigt, C. A. (2013) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2013.10.003 · Cited by 139
Suzuki, H., Ito, Y., Shinohara, M., Yamashita, S., Ichinose, S., Kishida, A., Oyaizu, T., Kayama, T., Nakamichi, R., Koda, N., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1522054113 · Cited by 138
Generation of improved humanized mouse models for human infectious diseases
Brehm, M. A., Wiles, M. V., Greiner, D. L., & Shultz, L. D. (2014) · Journal of Immunological Methods · doi:10.1016/j.jim.2014.02.011 · Cited by 137
van Agtmaal, E. L., André, L. M., Willemse, M. P., Cumming, S. A., van Kessel, I. D. G., van den Broek, W. J. A. A., Gourdon, G., Furling, D., Mouly, V., Monckton, D. G., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2016.10.014 · Cited by 147
Djukanovic, V., Smith, J., Lowe, K. S., Yang, M., Gao, H., Jones, S., Nicholson, M. G., West, A., Lape, J., Bidney, D. L., et al. (2013) · The Plant Journal · doi:10.1111/tpj.12335 · Cited by 136
Fan, Y., & Lin, X. (2018) · Genetics · doi:10.1534/genetics.117.300656 · Cited by 136
Maioli, A., Gianoglio, S., Moglia, A., Acquadro, A., Valentino, D., Milani, A. M., Prohens, J., Orzáez, D., Granell, A., Lanteri, S., et al. (2020) · Frontiers in Plant Science · doi:10.3389/fpls.2020.607161 · Cited by 141
Regulated control of gene therapies by drug-induced splicing
Mas, A., Hundley, A. A., Ranum, P. T., Tecedor, L., Muehlmatt, A., Lim, E., Lukashev, D. E., Sivasankaran, R., & Davidson, B. L. (2021) · Nature · doi:10.1038/s41586-021-03770-2 · Cited by 134
CRISPR-Cas in Streptococcus pyogenes
Rhun, A. L., Escalera-Maurer, A., Bratovič, M., & Charpentier, E. (2019) · RNA Biology · doi:10.1080/15476286.2019.1582974 · Cited by 143
Mitigating off-target effects in CRISPR/Cas9-mediated in vivo gene editing
Han, H. A., Pang, J. K. S., & Soh, B.-S. (2020) · Journal of Molecular Medicine · doi:10.1007/s00109-020-01893-z · Cited by 134
Delivery and therapeutic applications of gene editing technologies ZFNs, TALENs, and CRISPR/Cas9
LaFountaine, J. S., Fathe, K., & Smyth, H. D. C. (2015) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2015.08.029 · Cited by 111
Surrogate reporter-based enrichment of cells containing RNA-guided Cas9 nuclease-induced mutations
Ramakrishna, S., Cho, S. W., Kim, S., Song, M., Gopalappa, R., Kim, J., & Kim, S. (2014) · Nature Communications · doi:10.1038/ncomms4378 · Cited by 134
Yang, L., Grishin, D., Wang, G., Aach, J., Zhang, C., Chari, R., Homsy, J. G., Cai, X., Zhao, Y., Fan, J., et al. (2014) · Nature Communications · doi:10.1038/ncomms6507 · Cited by 133
Cebrian-Serrano, A., & Davies, B. (2017) · Mammalian Genome · doi:10.1007/s00335-017-9697-4 · Cited by 143
Zhang, D., Zhang, H., Li, T., Chen, K., Qiu, J., & Gao, C. (2017) · Genome biology · doi:10.1186/s13059-017-1325-9 · Cited by 133
Housden, B. E., Valvezan, A. J., Kelley, C., Sopko, R., Hu, Y., Roesel, C. L., Lin, S., Buckner, M., Tao, R., Yilmazel, B., et al. (2015) · Science Signaling · doi:10.1126/scisignal.aab3729 · Cited by 134
Highly specific targeted mutagenesis in plants using Staphylococcus aureus Cas9
Kaya, H., Mikami, M., Endo, A., Endo, M., & Toki, S. (2016) · Scientific Reports · doi:10.1038/srep26871 · Cited by 135
Gesicle-Mediated Delivery of CRISPR/Cas9 Ribonucleoprotein Complex for Inactivating the HIV Provirus
Campbell, L. A., Coke, L. M., Richie, C. T., Fortuno, L. V., Park, A. Y., & Harvey, B. K. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.10.002 · Cited by 140
Massively parallel kinetic profiling of natural and engineered CRISPR nucleases
Jones, S. K., Hawkins, J. A., Johnson, N. V., Jung, C., Hu, K., Rybarski, J. R., Chen, J. S., Doudna, J. A., Press, W. H., & Finkelstein, I. J. (2020) · Nature Biotechnology · doi:10.1038/s41587-020-0646-5 · Cited by 131
Repurposing CRISPR/Cas9 for in situ functional assaysPreprint
Malina, A., Mills, J. R., Cencic, R., Yan, Y., Fraser, J., Nederveen-Schippers, L. M., Paquet, M., Dostie, J., & Pelletier, J. (2013) · Genes & Development · doi:10.1101/gad.227132.113 · Cited by 132
Genome editing at the crossroads of delivery, specificity, and fidelity
Maggio, I., & Gonçalves, M. A. F. V. (2015) · Trends in biotechnology · doi:10.1016/j.tibtech.2015.02.011 · Cited by 135
An online bioinformatics tool predicts zinc finger and TALE nuclease off-target cleavage
Fine, E. J., Cradick, T. J., Zhao, C. L., Lin, Y., & Bao, G. (2013) · Nucleic Acids Research · doi:10.1093/nar/gkt1326 · Cited by 139
Promoting Cas9 degradation reduces mosaic mutations in non-human primate embryos
Tu, Z., Yang, W., Yan, S., Yin, A., Gao, J., Liu, X., Zheng, Y., Zheng, J., Li, Z., Yang, S., et al. (2017) · Scientific Reports · doi:10.1038/srep42081 · Cited by 135
Kumlehn, J., Pietralla, J., Hensel, G., Pacher, M., & Puchta, H. (2018) · Journal of Integrative Plant Biology · doi:10.1111/jipb.12734 · Cited by 142
CRISPR/Cas9 mediated genome engineering in Drosophila
Bassett, A. R., & Liu, J. (2014) · Methods · doi:10.1016/j.ymeth.2014.02.019 · Cited by 131
One-step generation of triple knockout CHO cell lines using CRISPR/Cas9 and fluorescent enrichment
Grav, L. M., Lee, J. S., Gerling, S., Kallehauge, T. B., Hansen, A. H., Kol, S., Lee, G. M., Pedersen, L. E., & Kildegaard, H. F. (2015) · Biotechnology Journal · doi:10.1002/biot.201500027 · Cited by 131
Engineering large animal models of human disease
Whitelaw, B., Sheets, T. P., Lillico, S. G., & Telugu, B. P. V. L. (2015) · The Journal of Pathology · doi:10.1002/path.4648 · Cited by 138
Cerbini, T. A., Funahashi, R., Luo, Y., Liu, C., Park, K., Rao, M. S., Malik, N., & Zou, J. (2015) · PLoS ONE · doi:10.1371/journal.pone.0116032 · Cited by 127
One-step generation of triple gene-targeted pigs using CRISPR/Cas9 system
Wang, X., Cao, C., Huang, J., Yao, J. T., Hai, T., Zheng, Q., Wang, X., Zhang, H., Qin, G., Cheng, J., et al. (2016) · Scientific Reports · doi:10.1038/srep20620 · Cited by 130
Crossing enhanced and high fidelity SpCas9 nucleases to optimize specificity and cleavage
Kulcsár, P. I., Tálas, A., Huszár, K., Ligeti, Z., Tóth, E., Weinhardt, N., Fodor, E., & Welker, E. (2017) · Genome biology · doi:10.1186/s13059-017-1318-8 · Cited by 134
RNA Strand Displacement Responsive CRISPR/Cas9 System for mRNA Sensing
Li, Y., Teng, X., Zhang, K., Deng, R., & Li, J. (2019) · Analytical Chemistry · doi:10.1021/acs.analchem.8b05238 · Cited by 128
Cardiac Pathophysiology and the Future of Cardiac Therapies in Duchenne Muscular Dystrophy
Meyers, T. A., & Townsend, D. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20174098 · Cited by 138
Self‐Assembled DNA Nanoclews for the Efficient Delivery of CRISPR–Cas9 for Genome Editing
Sun, W., Ji, W., Hall, J. M., Hu, Q., Wang, C., Beisel, C. L., & Gu, Z. (2015) · Angewandte Chemie · doi:10.1002/ange.201506030 · Cited by 132
TALEN-mediated targeting of HPV oncogenes ameliorates HPV-related cervical malignancy
Hu, Z., Ding, W., Zhu, D., Yu, L., Jiang, X., Wang, X., Zhang, C., Wang, L., Ji, T., Liu, D., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci78206 · Cited by 130
Recent Advances in Genome Editing Using CRISPR/Cas9
Ding, Y., Li, H., Chen, L., & Xie, K. (2016) · Frontiers in Plant Science · doi:10.3389/fpls.2016.00703 · Cited by 144
Implications of human genetic variation in CRISPR-based therapeutic genome editing
Scott, D. A., & Zhang, F. (2017) · Nature Medicine · doi:10.1038/nm.4377 · Cited by 129
Loureiro, A., & da Silva, G. J. (2019) · Antibiotics · doi:10.3390/antibiotics8010018 · Cited by 129
Pamies, D. (2018) · ALTEX · doi:10.14573/altex.1710081 · Cited by 127
Flynn, R., Grundmann, A., Renz, P. F., Haenseler, W., James, W., Cowley, S. A., & Moore, M. D. (2015) · Experimental Hematology · doi:10.1016/j.exphem.2015.06.002 · Cited by 128
Genome-wide specificity of prime editors in plants
Jin, S., Lin, Q., Luo, Y., Zhu, Z., Liu, G., Li, Y., Chen, K., Qiu, J., & Gao, C. (2021) · Nature Biotechnology · doi:10.1038/s41587-021-00891-x · Cited by 131
Engineering Synthetic Gene Circuits in Living Cells with CRISPR Technology
Jusiak, B., Cleto, S., Pérez‐Piñera, P., & Lu, T. K. (2016) · Trends in biotechnology · doi:10.1016/j.tibtech.2015.12.014 · Cited by 132
Nonintegrating Gene Therapy Vectors
Athanasopoulos, T., Munye, M. M., & Yáñez‐Muñoz, R. J. (2017) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2017.06.007 · Cited by 134
CRISPR/Cas9 gene-editing: Research technologies, clinical applications and ethical considerations
Memi, F., Ntokou, A., & Papangeli, I. (2018) · Seminars in Perinatology · doi:10.1053/j.semperi.2018.09.003 · Cited by 134
Polstein, L. R., Pérez‐Piñera, P., Koçak, D. D., Vockley, C. M., Bledsoe, P. J., Song, L., Safi, A., Crawford, G. E., Reddy, T. E., & Gersbach, C. A. (2015) · Genome Research · doi:10.1101/gr.179044.114 · Cited by 132
Biomedical applications of mRNA nanomedicine
Xiong, Q., Lee, G. Y., Ding, J., Li, W., & Shi, J. (2018) · Nano Research · doi:10.1007/s12274-018-2146-1 · Cited by 125
Mock, U., Machowicz, R., Hauber, I., Horn, S., Abramowski, P., Berdien, B., Hauber, J., & Fehse, B. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv469 · Cited by 129
Multigene disruption in undomesticated Bacillus subtilis ATCC 6051a using the CRISPR/Cas9 system
Zhang, K., Duan, X., & Wu, J. (2016) · Scientific Reports · doi:10.1038/srep27943 · Cited by 127
CRISPR/Cas9‐mediated genome editing: From basic research to translational medicine
Jacinto, F. V., Link, W., & Ferreira, B. I. (2020) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.14916 · Cited by 135
Clinical delivery of circular RNA: Lessons learned from RNA drug development
Young, T. L., Wang, K. C., Varley, A., & Li, B. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114826 · Cited by 130
CRISPR/Cas-Mediated Targeted Mutagenesis in Daphnia magna
Nakanishi, T., Kato, Y., Matsuura, T., & Watanabe, H. (2014) · PLoS ONE · doi:10.1371/journal.pone.0098363 · Cited by 125
A Cut above the Rest: Targeted Genome Editing Technologies in Human Pluripotent Stem Cells
Li, M., Suzuki, K., Kim, N. Y., Liu, G., & Belmonte, J. C. I. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.r113.488247 · Cited by 123
NmeCas9 is an intrinsically high-fidelity genome-editing platform
Amrani, N., Gao, X. D., Liu, P., Edraki, A., Mir, A., Ibraheim, R., Gupta, A., Sasaki, K. E., Wu, T., Donohoue, P. D., et al. (2018) · Genome biology · doi:10.1186/s13059-018-1591-1 · Cited by 128
Recent progress in genome engineering techniques in the silkworm, B ombyx mori
Daimon, T., Kiuchi, T., & Takasu, Y. (2013) · Development Growth & Differentiation · doi:10.1111/dgd.12096 · Cited by 124
Wang, G., Zhao, N., Berkhout, B., & Das, A. T. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.11.057 · Cited by 124
Precise Editing at DNA Replication Forks Enables Multiplex Genome Engineering in Eukaryotes
Barbieri, E. M., Muir, P., Akhuetie‐Oni, B. O., Yellman, C. M., & Isaacs, F. J. (2017) · Cell · doi:10.1016/j.cell.2017.10.034 · Cited by 126
The Current State and Future of CRISPR-Cas9 gRNA Design Tools
Wilson, L. O. W., O’Brien, A. R., & Bauer, D. C. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00749 · Cited by 124
Protospacer adjacent motif (PAM)-distal sequences engage CRISPR Cas9 DNA target cleavage
Cencic, R., Miura, H., Malina, A., Robert, F., Ethier, S., Schmeing, T. M., Dostie, J., & Pelletier, J. (2014) · PLoS ONE · doi:10.1371/journal.pone.0109213 · Cited by 117
From Genomics to Gene Therapy: Induced Pluripotent Stem Cells Meet Genome Editing
Hotta, A., & Yamanaka, S. (2015) · Annual Review of Genetics · doi:10.1146/annurev-genet-112414-054926 · Cited by 124
Omichi, R., Shibata, S. B., Morton, C. C., & Smith, R. J. H. (2019) · Human Molecular Genetics · doi:10.1093/hmg/ddz129 · Cited by 125
Lee, C. M., Cradick, T. J., Fine, E. J., & Bao, G. (2016) · Molecular Therapy · doi:10.1038/mt.2016.1 · Cited by 123
Applications of CRISPR-Cas Enzymes in Cancer Therapeutics and Detection
Huang, C., Lee, K.-C., & Doudna, J. A. (2018) · Trends in cancer · doi:10.1016/j.trecan.2018.05.006 · Cited by 119
Metadata
- Authors
- Fu, Y., Foden, J. A., Khayter, C., Maeder, M. L., Reyon, D., Joung, J. K., & Sander, J. D.
- Affiliations
- Harvard University (US)
- Massachusetts General Hospital (US)
- Corresponding author
- Joung, J Keith
- Sander, Jeffry D
- Venue
- Nature Biotechnology
- Published
- 2013-06-23
- Volume
- 31
- Issue
- 9
- Pages
- 822-826
- ISSN
- 0733-222X (ISSN-L)
- 1087-0156
- 1546-1696
- PMC
- PMC3773023
- OpenAlex
- W2077659966
- Cited by
- 3,292
- References
- 20
- Citations by year
- 2026: 140 · 2025: 181 · 2024: 206 · 2023: 208 · 2022: 246 · 2021: 254 · 2020: 280 · 2019: 274 · 2018: 278 · 2017: 269 · 2016: 314 · 2015: 254 · 2014: 291 · 2013: 90
- FWCI
- 141.80
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- Nature Biotechnology (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- Funders
- National Human Genome Research Institute (P50HG005550)
- National Institute of General Medical Sciences (DP1GM105378, R01GM088040)
- National Center for Chronic Disease Prevention and Health Promotion (DP1 GM105378)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA regulation and disease
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- CRISPR/Cas9, off-target cleavage, RNA-guided nucleases, mismatch tolerance, genome editing, mutagenesis, human cells, off-target sites
- MeSH terms
- Base Sequence, Endonucleases, Genetic Engineering, Humans, Molecular Sequence Data, Mutagenesis, K562 Cells, HEK293 Cells, CRISPR-Associated Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
